Stifel Financial Corp Reduces Stake in Natera, Inc. (NASDAQ:NTRA)

Stifel Financial Corp lessened its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 10.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,483 shares of the medical research company’s stock after selling 550 shares during the period. Stifel Financial Corp’s holdings in Natera were worth $569,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Farallon Capital Management LLC lifted its holdings in Natera by 13.6% in the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after acquiring an additional 532,874 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Natera by 3.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock valued at $315,194,000 after purchasing an additional 85,236 shares during the period. Duquesne Family Office LLC raised its position in Natera by 2.4% in the second quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock valued at $213,860,000 after purchasing an additional 45,500 shares during the period. Maverick Capital Ltd. lifted its stake in shares of Natera by 25.2% in the 3rd quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock valued at $170,119,000 after purchasing an additional 269,706 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Natera by 25.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock worth $156,092,000 after purchasing an additional 246,246 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other Natera news, insider Jonathan Sheena sold 3,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $125.67, for a total transaction of $377,010.00. Following the completion of the sale, the insider now directly owns 57,432 shares of the company’s stock, valued at approximately $7,217,479.44. This trade represents a 4.96 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rowan E. Chapman sold 1,767 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $170.24, for a total value of $300,814.08. Following the completion of the transaction, the director now directly owns 6,202 shares in the company, valued at approximately $1,055,828.48. The trade was a 22.17 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 130,932 shares of company stock worth $21,012,440. 7.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of research analyst reports. Leerink Partners upped their price objective on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Craig Hallum lifted their price objective on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Robert W. Baird lifted their price objective on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Piper Sandler increased their target price on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $152.67.

Natera Trading Down 1.7 %

NASDAQ:NTRA opened at $159.64 on Friday. The company has a market capitalization of $21.08 billion, a PE ratio of -90.70 and a beta of 1.63. Natera, Inc. has a 52-week low of $58.53 and a 52-week high of $175.63. The stock’s 50 day moving average price is $149.42 and its 200 day moving average price is $127.56. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue was up 63.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.95) earnings per share. On average, research analysts anticipate that Natera, Inc. will post -1.61 EPS for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.